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Adjunctive use of systematic retinal
thickness map analysis to monitor disease
activity in punctate inner choroidopathy
Savitha Madhusudhan1,2, Pearse A. Keane3 and Alastair K. Denniston1,2,4*
Abstract
A challenge in the management of ‘white dot syndromes’ is the lack of sensitive objective measures of disease
activity. Retinal thickness maps from spectral domain optical coherence tomography (SD-OCT) inform treatment
decisions in other retinal conditions such as age-related macular degeneration and diabetic maculopathy. In this
report, we demonstrate their value in providing quantitative monitoring of a patient with punctate inner
choroidopathy (PIC). Retinal thickness maps referenced against a baseline scan reliably detected focal areas of
increased macular volume in active PIC lesions during symptomatic episodes, highlighting these as ‘hot spots’ that
could be quantified, providing an objective basis for treatment decisions.
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Findings
Introduction
Punctate inner choroidopathy (PIC) is a rare idiopathic
inflammatory condition affecting the outer retina, retinal
pigment epithelium and choroid that mostly occurs in
young myopic females and predominantly affects the
posterior pole [1]. It runs a variable course, with mul-
tiple recurrences in up to a third of patients and can be
associated with severe visual loss when complicated by
choroidal neovascularisation (CNV) and subretinal fibro-
sis [2]. Stages in the evolution of PIC lesions on spectral
domain optical coherence tomography (SD-OCT) have
been described [3, 4]. Although blue wavelength fundus
autofluorescence (FAF) can help discriminate between
active and atrophic lesions, findings can sometimes be
ambiguous [5]. We describe the application of systematic
retinal thickness map analysis of SD-OCT (Heidelberg
Eye Explorer™, Heidelberg, Germany) as a useful adjunct
in detecting lesion activity in PIC.
Case example
A 43-year-old Caucasian female was diagnosed with PIC
after presenting with photopsia associated with active
retinal lesions and multifocal chorioretinal atrophic le-
sions in the macula in her left eye. Her right eye had
long-standing macular scarring with vision of ‘hand
movements’. Oral corticosteroid treatment for her active
PIC lesions resulted in visual acuity improving from 6/
12 to 6/6 in the left eye. It was noted that although treat-
ment response was not easily determined on non-
quantitative assessment of the SD-OCT images, reduc-
tion in lesion size could easily be detected and object-
ively measured using retinal thickness maps (Heyex™).
Recurrent exacerbations of the disease resulted in in-
creasing maintenance treatment (mycophenolate mofetil
1 g bid; oral prednisolone 10 mg od) with individual
flares being treated with intravitreal corticosteroid; a
choroidal neovascular membrane was treated with a
course of intravitreal bevacizumab injections. Retinal
thickness maps based on automated segmentation lines
delineating internal limiting membrane and Bruch’s
membrane proved consistently reliable, showing focal
retinal thickening in the form of ‘hot spots’ at sites
which were suspicious for new activity on SD-OCT
(Table 1). Following intravitreal steroid treatment, the
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thickness map returned towards baseline each time, cor-
responding with the resolution of symptoms (Fig. 1).
These maps also enabled an estimation of what
constituted a ‘symptomatic’ deterioration. Comparing
each ‘active’ episode to the preceding ‘quiescent’ visit
showed that the mean detectable change of retinal
thickness associated with symptoms was 60.2 μm
(range 12–103 μm). The average increase in retinal
thickness during a flare in the inner (1 mm), middle
(3 mm) and outer (6 mm) zones of the ETDRS macu-
lar grid was 18.2 μm (range 10–33 μm), 25.9 μm
(range 3–59 μm) and 12.6 μm (range 14–28 μm),
respectively, with more hot spots recurring in the
middle, inner and outer zones in that order (Table 1).
This patient has given specific consent for her clinical
data and images to be published.
Discussion
A major challenge in managing patients with ‘white dot
syndromes’ is the lack of sensitive measures of disease
activity that can provide objective guidance for treat-
ment decisions. This is particularly important when
dealing with sight-threatening conditions where systemic
treatment with immunosuppressants may be indicated,
such as PIC.
Our patient was highly sensitive to visual symptoms in
her ‘only’ eye, but similar changes may often be missed
by patients (e.g. if occurring in the worse-seeing eye).
For the clinician, the changes in PIC may be subtle and
may be missed on clinical examination or non-
quantitative assessment of imaging. In our dedicated
PIC clinic, all patients have longitudinally tracked retinal
thickness maps facilitating detection of new lesions even
in asymptomatic patients, guiding treatment decisions
and quantifying treatment response. This case highlights
how changes on these maps can easily be visualised, pro-
viding an objective correlate to the patient’s symptoms
and enabling confidence in treatment. The use of these
thickness maps enables rapid screening for new or chan-
ging lesions which can then be analysed in more detail
on the ‘b mode’ SD-OCT scans; thickness maps there-
fore augment rather than replace the ‘b scans’.
This technique depends on accurate segmentation of
the SD-OCT images, which can be readily checked prior
to interpretation of maps. Extensive chorioretinal scar-
ring may cause failure of automated segmentation but
can be easily overcome by applying manual segmenta-
tion. Decentration of the macular grid will also affect in-
dividual subfield thickness measurements, so all ‘follow-
up’ images should be acquired or interpreted against a
designated reference scan [6]. It should be noted that
the technique is not specific to the Heyex™ software.
Most OCT manufacturers provide retinal thickness
maps as standard, and therefore, this application should
be widely available for monitoring patients with PIC or
other white dot syndromes. Devices do, however, vary in
their resolution and in the accuracy of their registration
between baseline and follow-up scans. This may affect
the reliability of detecting change over time, particularly
the subtle but functionally significant changes seen in
many white dot syndromes.
In PIC, recurring inflammatory lesions occurring close
to fixation may lead to a significant loss of vision and
immunomodulatory treatment is advised. Additionally,
the clinician should be alert to the development of in-
flammatory CNV, which is a relatively common compli-
cation of PIC, and should be confirmed by retinal
angiography and timely treatment initiated including the
Table 1 Outcomes of methods used to detect active PIC lesions in the patient’s left eye
Symptom
episodes
Unaided Snellen visual
acuity (pinhole
vision when tested)
Clinically
identifiable
lesion
New changes
in FAF
New changes
in SD-OCT
‘Hot spots’ on
thickness map
Maximal increase in
thickness within a ‘hot spot’
compared to immediate
previous visit (μm)
Treatment
1 December
2014
6/6 No No Yes Yes 56 IVTA
27 January 2015 6/7.5 Yes No Yes Yes 102 IVTA
13 March 2015 6/9 (6/6) Doubtful FAF
unavailable
Yes Yes 103 IVTA
12 May 2015 6/6 No No Yes Yes 12 Intravitreal
dexamethasone
implant
11 August 2015 6/9 No FAF
unavailable
Yes Yes 21 IVTA
29 September
2015
6/9 No Doubtful Yes Yes 67 Intravitreal
dexamethasone
implant
FAF fundus autofluorescence, IVTA intravitreal triamcinolone
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use of anti-vascular endothelial growth factor (anti-
VEGF) therapy [7]. There is little data to support the use
of one immunosuppressant over another in PIC, but
Neri has reported on the combination of high-dose cor-
ticosteroid in combination with mycophenolate mofetil
(MMF) for the treatment of refractory inflammatory
CNV, including five eyes with PIC. In this series, the
regimen of three pulses of 1 g intravenous methylpred-
nisolone, oral prednisolone (starting at 1 mg/kg/day)
and MMF (1 g twice daily) was well tolerated and led to
stabilisation or improvement in visual acuity and stabil-
isation or reduction of lesion size in all lesions [8]. SD-
OCT is already a valued tool in the objective assessment
of macular oedema in uveitis and is increasingly finding
new applications [9]. In these instances, the use of ret-
inal thickness maps is helpful to ascertain lesion activity.
In conclusion, retinal thickness map tracking provides a
sensitive, reliable, objective way of monitoring PIC and,
in this era of multimodal imaging, it may prove a useful
adjunct in managing other conditions in the spectrum of
white dot syndromes.
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Fig. 1 Comparative retinal thickness maps and SD-OCT images from an active and subsequent quiescent phase of punctate inner choroidopathy
lesions in the patient’s left eye. SD-OCT during a symptomatic flare-up showing focal disruption of the RPE and ellipsoid zone associated with a
dome-shaped hyperreflective area (a, b) and corresponding retinal thickness maps showing an increase in retinal thickness in the form of increase
in the number, size and intensity of ‘hot spots’ compared to the reference with quantitative analysis of average change (c) in different subfields
of the macular grid. SD-OCT was repeated 23 days after intravitreal triamcinolone for the above episode showing involution of the active lesion (d, e)
and resolution of the hot spots on the corresponding retinal thickness maps compared to the same reference scan, together with quantitative analysis
of the average change in retinal thickness (f)
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